3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Small Cell Lung Carcinoma
23
Breast Neoplasms
17
Sarcoma
16
Carcinoma, Hepatocellular
10
Lung Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Stomach Neoplasms
8
Neoplasms
8
Triple Negative Breast Neoplasms
7
Ovarian Neoplasms
7
Nasopharyngeal Carcinoma
7
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
NSCLC
5
Colorectal Neoplasms
5
Carcinoma
5
Uterine Cervical Neoplasms
4
Thyroid Neoplasms
4
Pheochromocytoma
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Ovarian Epithelial
4
Recurrence
3
Paraganglioma
3
Non-squamous Non-small Cell Lung Cancer
3
Glioma
3
Fallopian Tube Neoplasms
3
Cholangiocarcinoma
3
Interventions
Doxorubicin
17
Cyclophosphamide
16
Ifosfamide
11
fludarabine
9
Radiotherapy
8
tazemetostat
4
pembrolizumab
4
pazopanib
4
Gemcitabine
4
pegfilgrastim
3
cixutumumab
3
Trabectedin
3
Radiation
3
Imatinib Mesylate
3
Filgrastim
3
Docetaxel
3
Dacarbazine
3
sargramostim
2
liposomal doxorubicin
2
fludarabine phosphate
2
brostallicin
2
aldesleukin
2
X-Rays
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Leukapheresis
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma, Synovial
×
anlotinib
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled